# BGT007 Cell Treatment of Nasopharyngeal Carcinoma

> **NCT05616468** · EARLY_PHASE1 · UNKNOWN · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 23 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** BGT007 Cell Injection
- **DRUG:** Fludarabine
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT05616468
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-30
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2022-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05616468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05616468, "BGT007 Cell Treatment of Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05616468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*